Hana Biosciences Licenses Cancer Products from Inex Pharmaceuticals
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 70 (Table of Contents)
Published: 6 Apr-2006
DOI: 10.3833/pdr.v2006.i70.534 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Hana Biosciences has been granted the worldwide license to develop and commercialize a panel of Phase II and preclinical anticancer therapies that are being developed by Inex as part of its Targeted Chemotherapy pipeline...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS